Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2289643 | 0.89 | MEN1 (0.39) | ALBPKMCYP2C9 | |
| SCHEMBL3638771 | 0.80 | KMT2A (0.36) | L3MBTL1SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL2290416 | 0.73 | ALDH1A1 (0.42) | L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4393229 | 0.72 | MEN1 (0.39) | L3MBTL1SMN1; SMN2ATMTSHRGAA | |
| SCHEMBL4379436 | 0.69 | MEN1 (0.43) | GAAALDH1A1CYP2C9 | |
| SCHEMBL13589015 | 0.69 | CYP3A4 (0.43) | L3MBTL1PKMSMN1; SMN2MAPK1ATM | |
| SCHEMBL8223748 | 0.68 | GPR6 (0.38) | GAACYP2C9 | |
| SCHEMBL4379541 | 0.68 | MEN1 (0.41) | SMN1; SMN2ALDH1A1CYP2C9 | |
| SCHEMBL4377612 | 0.68 | ALDH1A1 (0.44) | L3MBTL1SMN1; SMN2TSHRGAAALDH1A1 | |
| SCHEMBL4382730 | 0.68 | MEN1 (0.42) | GAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | ALB 3785/4885L3MBTL1 2561/4885PKM 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.